ASX 300 healthcare stock Sigma halted amid rumours of blockbuster Chemist Warehouse deal

Is Chemist Warehouse finally joining the ASX?

| More on:
Two happy pharmacists standing together in a pharmacy.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The shares of ASX 300 healthcare stock Sigma Healthcare Ltd (ASX: SIG) were pushing higher on Wednesday before being slammed into a trading halt this afternoon at the pharmacy operator's request.

According to the release, the company requested the halt pending the release of a big announcement. Its request states:

The trading halt is requested pending an announcement relating to a potential material transaction and is required to ensure Sigma shares are not trading on a misinformed basis.

What's going on with Sigma shares?

The rumour on the street is that Sigma shares have been halted today while it prepares to announce a reverse listing deal that will see pharmacy giant Chemist Warehouse listed on the Australian share market at long last.

According to the SMH, sources have told the media outlet that the two parties are close to agreeing a deal that would see Chemist Warehouse take board control and a majority ownership of Sigma.

The sources also claim that the deal could result in Sigma seeking to raise $400 million from investors to shore up its balance sheet and provide more liquidity.

Over at the AFR, it is reporting that the company will be seeking to raise $350 million to support the reverse listing of the privately owned Chemist Warehouse business.

Neither company has confirmed the reports yet. However, ASX 300 healthcare stock Sigma intends to release an announcement in relation to the "material transaction" before the market open on Friday.

So far, this news hasn't had an impact on Wesfarmers Ltd (ASX: WES) shares this afternoon. They have continued to rise despite the rumours. The conglomerate acquired Priceline-owner Australian Pharmaceutical Industries last year for almost $800 million.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Wesfarmers. The Motley Fool Australia has positions in and has recommended Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three healthcare workers look and point at at medical image
Share Market News

Pro Medicus shares surge 10% to crack $300 as healthcare leads ASX 200 sectors

Pro Medicus shares just keep on going, rising 625% over the past three years.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Can this biotech giant deliver healthy returns?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

UP 127% in a year, why is the Pro Medicus share price rocketing higher again today?

ASX investors are sending Pro Medicus shares flying higher on Thursday. But why?

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Healthcare Shares

These healthcare stocks could be set to double according to broker

Interested in gaining exposure to the healthcare sector? These options could be ones to watch. 

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Up 250% in a year, how much higher can this ASX healthcare share climb?  

The future looks promising for this biotech firm after delivering a record-quarterly result.

Read more »

shadow of a man looking out a window with arrows signifying falling share price
Healthcare Shares

Macquarie expects this ASX All Ords healthcare stock to fall 21% in FY26

The company faces several headwinds across multiple divisions.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Top broker names the best ASX healthcare shares to buy in FY26

Bell Potter has good things to say about these shares.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Healthcare Shares

Which ASX All Ords stock is jumping on record quarter?

This stock reported record sales during the past three months.

Read more »